Pasithea Therapeutics (KTTA) News
NASDAQ: KTTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.4787-0.0023 (-0.48%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KTTA news summary
We found 5 recent headlines mentioning Pasithea Therapeutics (KTTA): 1 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, KTTA is down 0.48% at $0.4787. The most recent story, "Pasithea Therapeutics Corp. Reports Initial Phase 1/1b Data for PAS-004 and FDA Clearance of IND for Phase 2 Trial", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Pasithea Therapeutics headlines
- Pasithea Therapeutics Corp. Reports Initial Phase 1/1b Data for PAS-004 and FDA Clearance of IND for Phase 2 TrialPasithea Therapeutics Corp. announced positive initial clinical data from its ongoing Phase 1/1b study of PAS-004 in adults with neurofibromatosis type 1-associated plexiform neurofibromas and…Nasdaq
- Pasithea Reports Tumor Shrinkage With PAS-004 In Neurofibromatosis Trial; Stock Up(RTTNews) - Pasithea Therapeutics Corp. (KTTA) reported reductions in the size of skin tumors in all 15 evaluable patients treated with its experimental drug PAS-004 in an ongoing Phase 1/1b study in…NasdaqKTTA, BRK.B
- Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis ConferencePasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early ActiviGlobeNewswire
- Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026GlobeNewswire
- Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026GlobeNewswire